Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial
Authors:
- 1 September 2021
- journal article
- research article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 6 (9) , 723-732
Abstract
No abstract availableKeywords
Funding Information
- Roche
- F. Hoffmann-La Roche (RO7049389)
This publication has 20 references indexed in Scilit:
- Hepatitis B core protein as a therapeutic targetExpert Opinion on Therapeutic Targets, 2017
- Hepatitis B cure: From discovery to regulatory approvalHepatology, 2017
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2017
- Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis BClinical and Molecular Hepatology, 2017
- High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core proteinProceedings of the National Academy of Sciences, 2015
- Core protein: A pleiotropic keystone in the HBV lifecycleAntiviral Research, 2015
- Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infectionJournal of Hepatology, 2015
- Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and managementJournal of Hepatology, 2014
- Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapyGut, 2005
- Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infectionHepatology, 2001